Analysts’ Weekly Ratings Updates for Elanco Animal Health (ELAN)

A number of research firms have changed their ratings and price targets for Elanco Animal Health (NYSE: ELAN):

• 5/16/2026 – Elanco Animal Health was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 5/11/2026 – Elanco Animal Health was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 5/7/2026 – Elanco Animal Health had its price target raised by Citigroup Inc. from $30.00 to $31.00. They now have a “buy” rating on the stock.
• 5/7/2026 – Elanco Animal Health had its price target raised by JPMorgan Chase & Co. from $28.00 to $30.00. They now have an “overweight” rating on the stock.
• 4/27/2026 – Elanco Animal Health was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.
• 4/18/2026 – Elanco Animal Health was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 4/15/2026 – Elanco Animal Health is now covered by Citigroup Inc.. They set a “buy” rating and a $30.00 price target on the stock.
• 3/27/2026 – Elanco Animal Health had its “sell (d+)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling at Elanco Animal Health

In other news, CEO Jeffrey N. Simmons bought 4,971 shares of Elanco Animal Health stock in a transaction dated Friday, May 15th. The shares were bought at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the purchase, the chief executive officer owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Rajeev A. Modi purchased 4,911 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were purchased at an average cost of $20.35 per share, with a total value of $99,938.85. Following the completion of the acquisition, the insider directly owned 160,812 shares in the company, valued at $3,272,524.20. The trade was a 3.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 1.14% of the stock is owned by insiders.

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.